With the advent of new agents in the treatment of multiple sclerosis. new treatment modalities have emerged (escalation-induction therapy) and the increased efficacy of the drugs has led to increased drug-related risks. The risk/benefit balance has become more carefully assessed. The increased need for reliable markers to predict prognosis-disability has also led to an increase in res... https://www.chiggate.com/shades-eq-09gi-hamptons-supply/